This clinical trial is focused on studying a type of blood cancer called Peripheral T-Cell Lymphoma (PTCL). The study aims to evaluate the safety and effectiveness of different treatment combinations for patients who have been newly diagnosed with this condition. The treatments being tested include a combination of drugs known as Bel-CHOP and Fol-COP. The Bel-CHOP regimen includes the drug Belinostat along with a standard chemotherapy regimen called CHOP, which consists of Cyclophosphamide, Doxorubicin, Vincristine Sulfate, and Prednisone. The Fol-COP regimen includes the drug Pralatrexate combined with a modified version of the CHOP regimen, excluding Doxorubicin.

The purpose of the study is to determine which treatment combination is more effective in improving the progression-free survival of patients, which means the length of time during and after treatment that a patient lives with the disease without it getting worse. The study will be conducted in two parts. The first part will focus on finding the best dose levels for Belinostat and Pralatrexate when used with the CHOP regimen. The second part will compare the effectiveness and safety of the Bel-CHOP and Fol-COP combinations against the CHOP regimen alone. Patients will receive treatment for up to six cycles, and their health will be monitored to assess the outcomes.

Participants in the study will receive their treatments through intravenous methods, which means the medication will be delivered directly into a vein. The study will also involve regular check-ups and assessments to monitor the patients’ response to the treatment and any side effects they may experience. The ultimate goal is to find a more effective treatment option for patients with newly diagnosed Peripheral T-Cell Lymphoma, potentially improving their quality of life and survival rates.